Clinical trials
First Line Therapy clinical trials
Below are recruiting first line therapy clinical trials, each written for real people, not researchers. We’re tracking 447 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06751940Recruiting
Personalized vaccine plus standard therapy for advanced colorectal cancer
This trial tests a personalized vaccine made from your tumor's unique features, combined with a standard second-line treatment, for colorectal cancer that has worsened after the first treatment. The goal is to see if this combination can help control the cancer better than standard therapy alone.
Nanchang, JiangxiAges 18–70 - NCT06751914Recruiting
Vaccine plus standard therapy for advanced colorectal cancer
This trial tests a personalized vaccine made from your tumor's unique markers, combined with standard second-line treatment, for colorectal cancer that has grown after first treatment. It aims to see if this combination can help control the cancer better.
Nanchang, JiangxiAges 18–70 - NCT06754059Recruiting
Pyrotinib with trastuzumab for HER2-positive breast cancer maintenance
This trial tests a combination of two targeted drugs (pyrotinib and trastuzumab) as maintenance therapy to keep HER2-positive breast cancer that has spread under control. It is for women who have already received some first-line treatment and are stable enough to continue therapy.
Fuzhou, FujianAges 18–70 - NCT07334431RecruitingPhase 1/Phase 2
A trial of fruquintinib, trastuzumab, and chemo for HER2-positive stomach cancer
This study tests a combination of three drugs (fruquintinib, trastuzumab, and XELOX chemotherapy) as the first treatment for people with advanced HER2-positive stomach or gastroesophageal junction cancer. The goal is to see if this combination is safe and effective for shrinking tumors.
Zhengzhou, HenanAges 18–75 - NCT07326137Recruiting
Pain relief and first-line treatment for advanced bile duct or pancreatic cancer
This study tests combining standard first-line cancer therapy with a nerve block to reduce pain in people with advanced bile duct or pancreatic cancer. It aims to see if this combination can improve pain control and quality of life.
Wuhan, HubeiAges Any age - NCT06870942RecruitingPhase 2
Radiation therapy for liver cancer that progresses after first immunotherapy
This trial tests whether adding targeted radiation to liver cancer patients who have limited progression after initial immunotherapy can help control the disease. It is for people with hepatocellular carcinoma (HCC) whose cancer has started to grow in just a few spots after their first PD-1 treatment.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06978400RecruitingPhase 2
Targeted therapy plus chemo for BRAF mutant colorectal cancer
This trial tests a combination of targeted therapy (dabrafenib) and two other drugs (cetuximab or panitumumab) plus standard chemotherapy (FOLFOX) as a first treatment for people with a specific type of metastatic colorectal cancer that has a BRAF V600E mutation and is microsatellite stable.
MoscowAges 18 years+ - NCT07050043RecruitingPhase 3
Low-dose nivolumab plus chemo vs standard chemo for advanced lung cancer
This trial tests whether a lower dose of the immunotherapy drug nivolumab combined with standard chemotherapy works better than chemotherapy alone for people with advanced or metastatic non-small cell lung cancer (NSCLC) that has not been treated before.
Alor Star, KedahAges 18 years+ - NCT06958419RecruitingPhase 2/Phase 3
Short radiation plus targeted drugs for advanced colon cancer
This trial tests a combination of short-course radiation, chemotherapy, targeted therapy (bevacizumab), and an immunotherapy drug (PD-1 inhibitor) for people with advanced colorectal cancer that has spread and is not curable with surgery. It aims to see if this approach can help shrink tumors and improve outcomes.
Guangzhou, GuangdongAges 18–75 - NCT06841172RecruitingPhase 3
Radiation vs treatment switch for limited liver cancer growth
This trial tests whether giving radiation to a few growing cancer spots while continuing your current treatment works better than switching to a new treatment right away. It's for people whose advanced liver cancer has only barely started to progress on their first therapy.
Jinan, ShandongAges 18–75 - NCT07117435RecruitingPhase 1
Targeted chemo into liver for colorectal cancer spread
This trial is testing a new way to give the chemotherapy drug paclitaxel directly into the liver (through a tiny tube) along with standard systemic treatment for people whose colorectal cancer has spread only to the liver and cannot be surgically removed. The goal is to see if this targeted approach works better than standard treatment alone.
Lishui, ZhejiangAges 18–75 - NCT06660355RecruitingPhase 2
Comparing two medicines for chronic graft-versus-host disease
This trial compares two treatments, ruxolitinib and prednisone, as the first therapy for chronic graft-versus-host disease (cGVHD), a condition where donor cells attack your body after a stem cell transplant. The goal is to see which medicine works better and has fewer side effects.
Miami, FloridaAges 18 years+ - NCT07501351RecruitingPhase 2
Comparing two therapies for advanced liver cancer after first treatment fails
This trial tests if a more intensive treatment is better than switching to another therapy for people with advanced liver cancer (HCC) that got worse after a first treatment with bevacizumab and sintilimab. It aims to find a more effective option for patients who need a next step.
Guangzhou, GuangdongAges 18–75 - NCT07232875RecruitingPhase 3
New drug combo for first-line advanced pancreatic cancer
This trial tests a new drug (HRS-4642) combined with standard chemotherapy as a first treatment for advanced pancreatic cancer that has spread. It may help shrink tumors and extend life.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT02394626RecruitingPhase 2
Surgery for glioblastoma that has come back
This trial studies whether operating on a brain tumor that has returned can help people with recurrent glioblastoma. It focuses on people whose scans suggest surgery is safe for important speech and movement brain areas.
InnsbruckAges 18 years+ - NCT07467330RecruitingPhase 3
Breast cancer trial: Adding capecitabine to standard treatment
This trial tests if adding a chemotherapy drug called capecitabine to the combination of dalpiciclib and hormone therapy works better than dalpiciclib and hormone therapy alone for advanced breast cancer that is hormone receptor-positive and HER2-negative. It is for people who have not had these treatments before.
Fuzhou, FujianAges 18 years+ - NCT07544784RecruitingPhase 2
AK104 plus radiation for colorectal cancer spread to liver
This study tests a new immunotherapy drug called AK104 combined with radiation therapy and standard chemotherapy for colorectal cancer that has spread to the liver. The goal is to see if adding AK104 and targeted radiation improves treatment outcomes compared to standard therapy alone.
ShanghaiAges 18 years+ - NCT06487585RecruitingPhase 4
Angiotensin II as first pressor after heart surgery
This trial tests if starting Angiotensin II early, instead of other blood pressure medications, can help heart surgery patients maintain safe blood pressure. It may be an option if you have low blood pressure after surgery despite receiving fluids.
Towson, MarylandAges 18 years+ - NCT06155396RecruitingPhase 2
Targeted drug combo for advanced cervical cancer
This trial tests a combination of two drugs: an antibody-drug conjugate (RC48-ADC) that targets HER2 on cancer cells, plus an immunotherapy (Zimberelimab) that helps your immune system attack the cancer. It is for people with advanced cervical cancer whose prior platinum-based chemotherapy has stopped working.
Bengbu, AnhuiAges 18 years+ - NCT06751953Recruiting
Neoantigen vaccine plus standard third-line therapy for colorectal cancer
This study tests a vaccine made from your tumor's unique proteins (neoantigens) combined with a standard third-line therapy for colorectal cancer that has worsened after two previous treatments. The goal is to see if this combination helps control the cancer better.
Nanchang, JiangxiAges 18–70 - NCT06751966Recruiting
Peptide vaccine plus standard therapy for advanced colorectal cancer
This trial tests a personalized peptide vaccine (based on your tumor's unique markers) combined with standard third-line therapy for colorectal cancer that has progressed after two prior treatments. The goal is to see if adding the vaccine can help control the cancer better.
Nanchang, JiangxiAges 18–70 - NCT03219593RecruitingPhase 2
Apatinib as first treatment for older adults with advanced stomach cancer
This trial tests a pill called apatinib as a first treatment for older adults with advanced stomach or gastroesophageal junction cancer. It might help if you cannot or do not want to have chemotherapy.
Bengbu, AnhuiAges 65 years+ - NCT05427383RecruitingPhase 2/Phase 3
KN026 plus chemo for HER2-positive stomach cancer after first treatment failure
This trial tests KN026 together with chemotherapy in people with HER2-positive advanced stomach (or gastro-esophageal junction) cancer that has already grown despite first-line treatment with trastuzumab plus chemotherapy. It may help by targeting HER2 while also using chemotherapy to control the cancer.
BeijingAges 18 years+ - NCT06221748RecruitingPhase 2/Phase 3
Study of DV with cadonilimab for HER2-positive stomach cancer
This trial tests a combination of two drugs (DV and cadonilimab) for people with HER2-positive stomach or gastroesophageal junction cancer that has grown after first treatment. It aims to see if this combo can help when standard options have stopped working.
Beijing, Beijing MunicipalityAges 18–75
Hear when a new First Line Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for first line therapy?
- Yes. Clin2 currently lists 447 recruiting first line therapy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a first line therapy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a first line therapy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.